Optimal NordiQC ratings for Optibodies™

Below a press release from Nordic BioSite about the Optibodies™, developed at BioSiteHisto.

optibodies_logotyp_rgb-1024x170

Press Release | Nordic Biosite AB

AUGUST 04, 2016

Täby, Sweden: – Nordic BioSite, the leading Scandinavian supplier of validated biotechnology products, has received further optimum ratings for Optibodies™, its innovative optimized antibodies.

The ratings were gained in external IHC quality assessments, produced by NordiQC (Nordic Immunohistochemical Quality Control), the independent scientific organization that promotes the quality and standardization of immunohistochemistry. NordiQC arranges schemes for pathology laboratories, assessing tissue-based assays, giving guidelines for improvement and providing optimal protocols.

Clinically important

Nordic BioSite Our experts have continuously been working with new, clinically important markers and antibodies. Our laboratory takes part in external quality assurance programs for immunohistochemistry. Immunohistochemical protocols with Optibodies™ have again been awarded excellent results in NordiQC schemes. We would like to promote the standardization and quality of immunohistochemistry of our laboratory with Optibodies™, which fulfill the optimal staining criteria of immunohistochemistry according to the NordiQC assessments.

The latest series of NordiQC test schemes (runs) produced impressive results with eight antibodies from the Optibodies™ range:

Cat. no. Antibody Clone NordiQC run
BSH-7124-1 Cytokeratin PAN BS5 Run 41 & 47
BSH-7385-1 Synaptophysin BS15 Run 43
BSH-2002-1 Napsin A BS10 Run 44
BSH-7959-1 SOX10 BS7 Run 45
BSH-7402-1 EpCAM BS14 Run 45
BSH-2008-1 CD34 BS72 Run 46
BSH-7123-1 CK5 BS42 Run 46

 

Optimum results

NordiQC Runs 41 and run 47 proved CKpan (Clone BS5) as a broad-spectrum cytokeratin antibody optimized for carcinoma diagnostics, offering strong intensity with no background and unspecific label.

Run 43 produced favorable results for Synaptophysin (Clone BS15). In neuroendrocrine tumor and control tissue of appendix (neuronal cells in muscularis propria of appendix), showing specific staining with strong and intensive label, along with high intensity staining of goblet cells in crypts of appendix epithelia.

Run 44 showed a similar result for Napsin A (Clone BS10), which is used as a differential marker of the lung adenocarcinoma vs. squamous cell carcinoma., again producing excellent staining specificity and intensity.

Run 45 produced good news about two different Optibodies in assessment: EpCAM (BS14) and SOX10 (BS7). EpCAM’s high-quality performance was proved with different staining platforms, demonstrating the advantages of alkaline antigen retrieval in offering optimal staining pattern without special antigen retrieval buffers. The same run also demonstrated SOX10 (BS7) as an impressive addition for melanoma diagnostics, effectively marking desmoplastic and spindle cell melanoma with strong intensity and no noise.

The following test (Run 46) again produced favorable results for two Optibodies, CD34 (BS72) and CK5 (BS42), while the final Run 47 archived optimal broad spectrum results for Cytokeratin 20 (BS101) along with CKPan.